- Home
- FMST vs IGC Comparison
FMST vs IGC Comparison
Compare FMST & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | IGC |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | Canada | United States |
| Employees | 2 | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 28.1M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | FMST | IGC |
|---|---|---|
| Price | $1.74 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 108.1K | ★ 506.0K |
| Earning Date | 05-21-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $0.24 |
| 52 Week High | $4.57 | $0.50 |
Technical Indicators
Market Signals| Indicator | FMST | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 42.74 |
| Support Level | $1.73 | $0.25 |
| Resistance Level | $1.94 | $0.31 |
| Average True Range (ATR) | 0.13 | 0.01 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 72.13 | 38.46 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.